Skip to content

   Pharma Publications

Neuropsychopharmacology
  • VTA-ACC dopaminergic circuit mediates trait anxiety-related observational learning of social avoidance in male mice
    Published on 2025-06-12
    6 months ago
  • The neural and psychophysiological effects of cannabidiol in youth with alcohol use disorder: A randomized controlled clinical trial
    Published on 2025-06-11
    6 months ago
  • Prefrontal corticotropin-releasing factor promotes resilience to social stress
    Published on 2025-06-10
    6 months ago
  • Sitagliptin as a therapeutic approach for social anxiety disorder: the role of DPP4 and NPY in modulating social fear and comorbid depressive-like behavior in mice
    Published on 2025-06-09
    6 months ago
  • Merkel cell stimulation in fear and sensory signaling
    Published on 2025-06-07
    6 months ago
  • Prelimbic cortical excitatory overdrive and inhibitory underdrive accompany environmental suppression of food seeking
    Published on 2025-06-06
    6 months ago
  • One step at a time: use of single-session rTMS to test novel targets for substance use disorders
    Published on 2025-06-06
    6 months ago
« Previous 1 … 19 20 21 22 23 … 143 Next »
Journal of Psychopharmacology
  • Challenges for switching central nervous system and psychiatric medication products: A review of the literature
    Published on 2025-01-31
    10 months ago
  • Systemic bupropion treatment reduces long-access cocaine self-administration in male and female rats
    Published on 2025-01-30
    10 months ago
  • Toward effective oxytocin interventions in autism: Overcoming challenges and harnessing opportunities
    Published on 2025-01-25
    11 months ago
  • Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review
    Published on 2025-01-20
    11 months ago
  • A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study)
    Published on 2025-01-20
    11 months ago
  • Associations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study
    Published on 2025-01-07
    11 months ago
  • Haloperidol dopamine receptor occupancy and antagonism correspond to delirium agitation scores and EPS risk: A PBPK-PD modeling analysis
    Published on 2025-01-04
    11 months ago
« Previous 1 … 19 20 21 22 23 … 134 Next »
European Neuropsychopharmacology
  • Redefining schizophrenia treatment with muscarinic modulation—A perspective
    Published on 2024-12-06
    1 year ago
  • Examining the impact of comorbid posttraumatic stress disorder on ketamine’s real-world effectiveness in treatment-resistant depression
    Published on 2024-12-06
    1 year ago
  • Dilemmas in psychedelic medicine: From ethics to regulation and equity
    Published on 2024-12-05
    1 year ago
  • Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia
    Published on 2024-12-03
    1 year ago
  • Risk of mortality and complications in people with depressive disorder and diabetes mellitus: A 20-year population-based propensity score-matched cohort study
    Published on 2024-11-30
    1 year ago
  • Rare Genetic variation in schizophrenia: Are the most obvious ‘druggable pathways’ hiding in plain sight?
    Published on 2024-11-29
    1 year ago
  • Valproate’s impact on future generations — A call for stricter guidelines for maternal and paternal use
    Published on 2024-11-29
    1 year ago
« Previous 1 … 19 20 21 22 23 … 153 Next »

   Pharma Pub